51.80p-0.70 (-1.33 %)23 Nov 2020, 16:43
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Diurnal Group PLC Fundamentals

Company NameDiurnal Group PLCLast Updated2020-11-23
IndustryDrug Manufacturers - Specialty & GenericSectorHealthcare
Shares in Issue138.325 mMarket Cap£71.65 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.04EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0Debt Equity Ratio0
Asset Equity Ratio1.1409Cash Equity Ratio0.8395
Quick Ratio6.2650Current Ratio7.52
Price To Book Value0ROCE0

Diurnal Group PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Diurnal Group PLC Company Financials

Tangible Assets£23,000.00£33,000.00£26,000.00£18,000.00
Intangible Assets£79,000.00£49,000.00£16,000.00£4,000.00
Investments£1.67 m000
Total Fixed Assets£1.77 m£82,000.00£42,000.00£22,000.00
Stocks£1.24 m£672,000.00£123,000.000
Cash & Equivalents£15.43 m£9.15 m£17.28 m£8.88 m
Other Assets0000
Total Assets£20.98 m£13.46 m£22.54 m£23.93 m
Creditors within 1 year£2.56 m£2.50 m£5.66 m£3.34 m
Creditors after 1 year£36,000.00£16,000.000£3.51 m
Other Liabilities0000
Total Liabilities£2.59 m£2.52 m£5.66 m£6.85 m
Net assets£18.39 m£10.94 m£16.88 m£17.08 m
Called up share capital£6.08 m£4.23 m£3.07 m£2.62 m
Share Premium£50.97 m£42.15 m£37.77 m£23.68 m
Profit / Loss-£5.28 m-£14.40 m-£16.91 m-£12.15 m
Other Equity£18.39 m£10.94 m£16.88 m£17.08 m
Preference & Minorities0000
Total Capital Employed£18.39 m£10.94 m£16.88 m£17.08 m
Debt Ratio000£0.17
Assets / Equity1.14091.14091.14091.1409
Cash / Equity0.83950.83950.83950.8395
Cash Flow2020201920182017
Cash from operating activities-£4.81 m-£13.74 m-£12.76 m-£10.47 m
Cashflow before financing£5.86 m-£8.21 m-£2.87 m-£10.42 m
Increase in Cash£5.93 m-£8.15 m£8.20 m-£7.25 m
Turnover£6.31 m£1.04 m£73,000.000
Cost of sales£668,000.00£224,000.00£15,000.000
Gross Profit£5.64 m£820,000.00£58,000.000
Operating Profit-£5.39 m-£14.53 m-£16.78 m-£12.06 m
Pre-Tax profit-£5.28 m-£14.40 m-£16.91 m-£12.15 m

Diurnal Group PLC Company Background

ActivitiesDiurnal Group PLC is a specialty pharmaceutical company developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism, andHypothyroidism. The company has two products in late-stage clinical development targeting Adrenal diseases; Chronocort to be used for the treatment of Congenital Adrenal Hyperplasia and Adrenal Insufficiency in Adults and Infacort which isto be used for the same conditions in children. Its main country of operation is the United Kingdom.
Latest Interim Date11 Feb 2020
Latest Fiscal Year End Date15 Sep 2020

Diurnal Group PLC Directors

2017-11-08Mr. Ian ArdillExecutive Director,Chief Financial Officer and Company Secretary
2020-10-16Mr. John GoddardDirector
2020-06-30Mr. Peter Vance AllenChairman
2020-10-16Dr. Samuel Cameron Williams Chairman (Interim)
2020-10-29Martin James WhitakerChief Executive Officer
2020-10-29Richard John Martin RossChief Scientific Officer
2020-10-16Alan Michael RaymondDirector
2020-10-19Mr. Richard Edward Bungay Chief Financial Officer & Company Secretary

Diurnal Group PLC Contact Details

Company NameDiurnal Group PLC
Address1 Callaghan Square, Cardiff, CF10 5BT

Diurnal Group PLC Advisors

StockbrokerPanmure Gordon (UK) Ltd
Phone+44 2078862500
Financial PR AdviserFTI Consulting Inc
Phone+44 2037271000
Fax+44 2037271007
BankNational Westminster Bank PLC
Phone+44 1132313000
Fax+44 1132313200
SolicitorEversheds LLP
Phone+44 2079194500
Fax+44 2079194919
RegistrarCapita Asset Services
Phone+44 8716640300
Fax+44 2086392342
Nominated AdviserNumis Securities Limited
Phone+44 2072601000
Fax+44 2072601001
StockbrokerNumis Securities Limited
Phone+44 2072601000
Fax+44 2072601001